JEADV Clinical Practice (Jun 2023)
Effectiveness and tolerability of calcipotriol/betamethasone aerosol foam in patients with psoriasis vulgaris in real‐life setting: A prospective, noninterventional, multicenter observational study in Austria
Abstract
Abstract Background For the topical treatment of plaque psoriasis, vitamin D analogues and corticosteroids are used as a fixed combination, which is available in different galenic preparations. Objectives The aim of this study was to investigate the effectiveness and tolerability of calcipotriol/betamethasone (Cal/BD) cutaneous foam in a real‐world setting. Methods Overall, 107 adult patients with at least mild plaque psoriasis as measured by the Investigator Global Assessment (IGA) were included and treated for 4 weeks. Affected body surface area (BSA), plaque locations, and Psoriasis Area and Severity Index (PASI) were documented at baseline, after 4 weeks and at the end of the study. Pruritus, overall patient satisfaction, tolerability and convenience of use, as well as quality of life (DLQI) were also evaluated. Results In total, 96% of the patients suffered from mild to moderate psoriasis vulgaris. Of all patients included, 76% had previously received topical therapy. Under treatment with Cal/BD aerosol foam, the mean IGA score was reduced from 2.49 to 1.28 points (p < 0.001). The mean PASI score was reduced from 7.01 to 3.58 (p < 0.001). BSA was improved from 9.92% to 4.19% (p < 0.001) and the DLQI from 7.81 to 2.43 points (p < 0.001). Over 88% (84/95 patients) were very satisfied or satisfied with Cal/BD aerosol foam. The treatment was described as soothing (63/89), cooling (70/89), and itch relieving (53/84). Lack of efficacy was documented as an adverse event (AE) in four of 107 patients. No other AEs were observed. Conclusions The treatment of psoriasis vulgaris with Cal/BD aerosol foam was demonstrated to be effective, well tolerated and associated with high patient satisfaction.
Keywords
